Breaking News Instant updates and real-time market news.

TODAY'S FREE FLY STORIES

Hot Stocks
HF Foods Group appoints Russell Libby to board of directors » 08:10
07/02/20
07/02
08:10
07/02/20
08:10
HFFG

HF Foods Group

$8.88 /

-0.14 (-1.55%)

HF Foods Group welcomes…

HF Foods Group welcomes Russell Libby to the Company's board of directors effective July 1, 2020. Pursuant to the previous 8K filing and announcement dated March 23, 2020, Libby has replaced the outgoing director, Zhehui Ni, who resigned effective June 30, 2020 due to personal and professional obligations. As a result of the change, the Company's board of directors remained composed of five directors, including three independent directors and two inside directors. From 2007 to 2019, Libby held numerous leadership positions at Sysco Corp. and most recently served as the company's executive vice president and corporate secretary.

ShowHide Related Items >><<
HFFG HF Foods Group
$8.88 /

-0.14 (-1.55%)

HFFG HF Foods Group
$8.88 /

-0.14 (-1.55%)

Recommendations
Constellation Brands price target raised to $185 from $176 at Deutsche Bank » 08:09
07/02/20
07/02
08:09
07/02/20
08:09
STZ

Constellation Brands

$185.60 /

+11.17 (+6.40%)

Deutsche Bank analyst…

Deutsche Bank analyst Steve Powers raised the firm's price target on Constellation Brands to $185 from $176 and keeps a Hold rating on the shares following the company's Q2 results. The analyst shares Constellation's "cautious optimism" for underlying demand sustainability, improving shipment trends in beer, and progress in underlying free cash flow generation.

ShowHide Related Items >><<
STZ Constellation Brands
$185.60 /

+11.17 (+6.40%)

STZ Constellation Brands
$185.60 /

+11.17 (+6.40%)

07/02/20 UBS
Constellation Brands price target raised to $208 from $192 at UBS
07/02/20 Jefferies
Constellation Brands price target raised to $238 from $224 at Jefferies
07/02/20 Citi
Constellation Brands price target raised to $200 from $176 at Citi
07/02/20 HSBC
Constellation Brands price target raised to $170 from $147 at HSBC
STZ Constellation Brands
$185.60 /

+11.17 (+6.40%)

STZ Constellation Brands
$185.60 /

+11.17 (+6.40%)

STZ Constellation Brands
$185.60 /

+11.17 (+6.40%)

STZ Constellation Brands
$185.60 /

+11.17 (+6.40%)

Recommendations
BioNTech price target raised to $42 from $37 at SVB Leerink » 08:09
07/02/20
07/02
08:09
07/02/20
08:09
BNTX

BioNTech

$64.14 /

-2.595 (-3.89%)

, PFE

Pfizer

$33.74 /

+1.05 (+3.21%)

SVB Leerink analyst Daina…

SVB Leerink analyst Daina Graybosch raised the firm's price target on BioNTech (BNTX) to $42 from $37 and keeps a Market Perform rating on the shares. The analyst notes that the increase reflects an assumed increase in probability of technical and regulatory success after the company and partner Pfizer (PFE) reported immunogenicity data for 36 subjects vaccinated with BNT-162b1, a modRNA vaccine against the receptor-binding domain of the SARS-CoV-2 spike protein. Further, Graybosch also expects additional immunogenicity data in the coming weeks to be positive, which, likely, will result in more upside for BioNTech's stock.

ShowHide Related Items >><<
BNTX BioNTech
$64.14 /

-2.595 (-3.89%)

BNTX BioNTech
$64.14 /

-2.595 (-3.89%)

07/02/20 Bryan Garnier
BioNTech price target raised to $62.50 from $50 at Bryan Garnier
07/01/20 Goldman Sachs
Pfizer COVID-19 vaccine data 'encouraging,' says Goldman Sachs
06/30/20 H.C. Wainwright
BioNTech downgraded to Neutral from Buy at H.C. Wainwright
06/25/20 H.C. Wainwright
BioNTech price target lowered to $63 from $69 at H.C. Wainwright
PFE Pfizer
$33.74 /

+1.05 (+3.21%)

06/29/20 Mizuho
Pfizer resumed with a Buy at Mizuho
06/25/20 Piper Sandler
Aptevo Therapeutics price target raised to $24 from $18.50 at Piper Sandler
PFE Pfizer
$33.74 /

+1.05 (+3.21%)

BNTX BioNTech
$64.14 /

-2.595 (-3.89%)

  • 06
    Feb
  • 10
    Oct
PFE Pfizer
$33.74 /

+1.05 (+3.21%)

BNTX BioNTech
$64.14 /

-2.595 (-3.89%)

PFE Pfizer
$33.74 /

+1.05 (+3.21%)

BNTX BioNTech
$64.14 /

-2.595 (-3.89%)

PFE Pfizer
$33.74 /

+1.05 (+3.21%)

BNTX BioNTech
$64.14 /

-2.595 (-3.89%)

Hot Stocks
Credit Acceptance announces change of location of Annual Meeting of Shareholders » 08:09
07/02/20
07/02
08:09
07/02/20
08:09
CACC

Credit Acceptance

$420.69 /

+1.09 (+0.26%)

Credit Acceptance…

Credit Acceptance announced that, because of the continuing public health concerns relating to the COVID-19 pandemic, and in consideration of the health and well-being of shareholders and other meeting participants, the Company's annual meeting of shareholders to be held on Wednesday, July 15, 2020, at 8:00 a.m., Eastern time, will not be held at the Company's principal executive offices, but instead will be held solely by means of remote communication in a virtual meeting format by live audio webcast over the Internet. Shareholders will not be able to attend the Annual Meeting physically in person.

ShowHide Related Items >><<
CACC Credit Acceptance
$420.69 /

+1.09 (+0.26%)

CACC Credit Acceptance
$420.69 /

+1.09 (+0.26%)

06/03/20 Stephens
Stephens says Santander Consumer may benefit if Wells pulling back on auto loans
05/29/20 BMO Capital
Credit Acceptance price target raised to $337 from $316 at BMO Capital
04/06/20 BTIG
Credit Acceptance price target lowered to $160 from $190 at BTIG
03/19/20 BTIG
Credit Acceptance price target lowered to $190 from $340 at BTIG
CACC Credit Acceptance
$420.69 /

+1.09 (+0.26%)

CACC Credit Acceptance
$420.69 /

+1.09 (+0.26%)

Hot Stocks
Diversified Healthcare provides segment update amid COVID-19 pandemic » 08:09
07/02/20
07/02
08:09
07/02/20
08:09
DHC

Diversified Healthcare Trust

$4.45 /

+0.03 (+0.68%)

, FVE

Five Star Senior Living

$4.03 /

+0.115 (+2.94%)

The company said…

The company said Diversified Healthcare Trust's (DHT) office segment, which contains medical office and life science assets, has maintained strength through the pandemic. As of June 30, DHC had granted rent deferrals equal to $2.2M in its office segment, which represents only 0.6% of DHC's annualized total revenues. During Q2, DHC had collected approximately 99% of its office segment rents that were due in April, May and June, after giving effect to rent deferrals. In light of the pandemic, DHC has worked closely with its operator, Five Star Senior Living (FVE), to ensure that early measures were taken at DHC's senior living communities, including active engagement by Five Star with its employees who are responsible for implementing protocols from the Centers for Disease Control and Prevention and/or local-equivalent public health authorities and other best practices measures. As a result of these measures, DHC's SHOP segment has maintained occupancies that are generally consistent with its peers and slightly better than DHC's expectations. As of March 31, April 30 and May 31, occupancy in DHC's SHOP Segment was 81.6%, 79.5% and 78.2%%, respectively. As of June 30, occupancy in DHC's SHOP Segment was 77.4%.

ShowHide Related Items >><<
DHC Diversified Healthcare Trust
$4.45 /

+0.03 (+0.68%)

DHC Diversified Healthcare Trust
$4.45 /

+0.03 (+0.68%)

06/08/20 JMP Securities
Diversified Healthcare Trust resumed with a Market Perform at JMP Securities
05/19/20 RBC Capital
Diversified Healthcare Trust price target lowered to $3 from $7 at RBC Capital
03/11/20 Mizuho
Sabra Health Care to be pressured by coronavirus at facility, says Mizuho
01/16/20 Wells Fargo
Diversified Healthcare Trust cut to Equal Weight from Overweight at Wells Fargo
FVE Five Star Senior Living
$4.03 /

+0.115 (+2.94%)

10/14/19 BofA
Senior Housing resumed with an Underperform at BofA/Merrill
DHC Diversified Healthcare Trust
$4.45 /

+0.03 (+0.68%)

DHC Diversified Healthcare Trust
$4.45 /

+0.03 (+0.68%)

FVE Five Star Senior Living
$4.03 /

+0.115 (+2.94%)

DHC Diversified Healthcare Trust
$4.45 /

+0.03 (+0.68%)

Recommendations
Activision Blizzard price target raised to $90 from $75 at Needham » 08:08
07/02/20
07/02
08:08
07/02/20
08:08
ATVI

Activision Blizzard

$78.06 /

+2.17 (+2.86%)

Needham analyst Laura…

Needham analyst Laura Martin raised the firm's price target on Activision Blizzard to $90 from $75 and keeps a Buy rating on the shares. The analyst cites the expansion of the company's total addressable market with live sports and cinemas going dark as well as higher revenues being generated by the COVID-19 lockdowns. Martin adds that eSports should become a "key upside driver" for Activision Blizzard as the company has launched its second pro league based on its Call of Duty game and as "parents understand" the social aspect of videogames during the shelter-in-place period.

ShowHide Related Items >><<
ATVI Activision Blizzard
$78.06 /

+2.17 (+2.86%)

ATVI Activision Blizzard
$78.06 /

+2.17 (+2.86%)

07/01/20 BofA
BofA makes 14 additions, four deletions from US 1 list
06/29/20 Benchmark
Activision Blizzard price target raised to $85 from $77 at Benchmark
06/15/20 Stephens
Electronic Arts seems like best fit as buyer for WB Interactive, says Stephens
06/15/20 Oppenheimer
EA makes 'most sense' as potential buyer of Warner gaming unit, says Oppenheimer
ATVI Activision Blizzard
$78.06 /

+2.17 (+2.86%)

ATVI Activision Blizzard
$78.06 /

+2.17 (+2.86%)

ATVI Activision Blizzard
$78.06 /

+2.17 (+2.86%)

ATVI Activision Blizzard
$78.06 /

+2.17 (+2.86%)

Hot Stocks
Post Holdings appoints Dorothy Burwell to board of directors » 08:08
07/02/20
07/02
08:08
07/02/20
08:08
POST

Post Holdings

$87.39 /

-0.1 (-0.11%)

Post Holdings announced…

Post Holdings announced Dorothy Burwell, Partner at The Finsbury Group has been appointed to its Board of Directors, effective July 1, 2020. With the addition of Ms. Burwell, the Board now consists of ten members. In 2008, she joined Finsbury, a global strategic communications consultancy part of WPP, and in 2015, she was promoted to Partner with a variety of responsibilities across client relationship management, company marketing and business development.

ShowHide Related Items >><<
POST Post Holdings
$87.39 /

-0.1 (-0.11%)

POST Post Holdings
$87.39 /

-0.1 (-0.11%)

06/22/20 Goldman Sachs
Post Holdings upgraded to Buy from Neutral at Goldman Sachs
05/04/20 Wells Fargo
Post Holdings price target lowered to $110 from $120 at Wells Fargo
04/09/20
Fly Intel: Top five analyst initiations
04/09/20 Citi
Post Holdings assumed with a Buy at Citi
POST Post Holdings
$87.39 /

-0.1 (-0.11%)

Syndicate
SunPower's planned spin-off, Maxeon Solar Technologies, files Form 20-F » 08:07
07/02/20
07/02
08:07
07/02/20
08:07
SPWR

SunPower

$7.64 /

-0.045 (-0.59%)

SunPower announced that…

SunPower announced that its planned spin-off, Maxeon Solar Technologies, filed an initial Form 20-F registration statement with the U.S. SEC. The form includes a detailed business overview with strategy, financials and competitive strengths relating to Maxeon Solar and the spin-off. SunPower anticipates closing the planned spin-off of Maxeon Solar during the third quarter. In May, Maxeon Solar's future investor and long-time partner Tianjin Zhonghuan Semiconductor Co. received necessary regulatory approval from the China State Administration for Market Regulation.

ShowHide Related Items >><<
SPWR SunPower
$7.64 /

-0.045 (-0.59%)

SPWR SunPower
$7.64 /

-0.045 (-0.59%)

06/02/20 Roth Capital
Roth says loan securitizations reopening a positive for residential solar names
05/28/20 JPMorgan
SunPower price target raised to $10 from $9 at JPMorgan
04/24/20 Morgan Stanley
Federal support for renewables could come in summer, says Morgan Stanley
04/03/20 Barclays
Barclays halves SunPower target to $2.50, sees risk of insolvency
SPWR SunPower
$7.64 /

-0.045 (-0.59%)

  • 21
    Nov
SPWR SunPower
$7.64 /

-0.045 (-0.59%)

SPWR SunPower
$7.64 /

-0.045 (-0.59%)

Hot Stocks
Tesla rallies after Q2 deliveries of 90,650 top 83,071 estimate  08:07
07/02/20
07/02
08:07
07/02/20
08:07
TSLA

Tesla

$1,118.00 /

+39 (+3.61%)

 
ShowHide Related Items >><<
TSLA Tesla
$1,118.00 /

+39 (+3.61%)

TSLA Tesla
$1,118.00 /

+39 (+3.61%)

07/02/20 Wedbush
Wedbush boosts Tesla target to $1,250 with new bull case of $2,000
07/01/20 Wedbush
'Impressive' trajectory in June bodes well for Tesla deliveries, says Wedbush
06/30/20 Oppenheimer
Oppenheimer anticipates in-line or ahead of consensus Q2 deliveries for Tesla
06/30/20 JMP Securities
Tesla price target raised to $1,050 from $1,001 at JMP Securities
TSLA Tesla
$1,118.00 /

+39 (+3.61%)

  • 14
    Feb
TSLA Tesla
$1,118.00 /

+39 (+3.61%)

TSLA Tesla
$1,118.00 /

+39 (+3.61%)

TSLA Tesla
$1,118.00 /

+39 (+3.61%)

TSLA Tesla
$1,118.00 /

+39 (+3.61%)

Hot Stocks
Tesla jumps 9% to $1,221.19 after Q2 deliveries top estimates  08:06
07/02/20
07/02
08:06
07/02/20
08:06
TSLA

Tesla

$1,118.00 /

+39 (+3.61%)

 
ShowHide Related Items >><<
TSLA Tesla
$1,118.00 /

+39 (+3.61%)

TSLA Tesla
$1,118.00 /

+39 (+3.61%)

07/02/20 Wedbush
Wedbush boosts Tesla target to $1,250 with new bull case of $2,000
07/01/20 Wedbush
'Impressive' trajectory in June bodes well for Tesla deliveries, says Wedbush
06/30/20 Oppenheimer
Oppenheimer anticipates in-line or ahead of consensus Q2 deliveries for Tesla
06/30/20 JMP Securities
Tesla price target raised to $1,050 from $1,001 at JMP Securities
TSLA Tesla
$1,118.00 /

+39 (+3.61%)

  • 14
    Feb
TSLA Tesla
$1,118.00 /

+39 (+3.61%)

TSLA Tesla
$1,118.00 /

+39 (+3.61%)

TSLA Tesla
$1,118.00 /

+39 (+3.61%)

TSLA Tesla
$1,118.00 /

+39 (+3.61%)

Hot Stocks
Kratos Defense receives $30M C5ISR contract awards » 08:06
07/02/20
07/02
08:06
07/02/20
08:06
KTOS

Kratos Defense

$15.33 /

-0.315 (-2.01%)

Kratos Defense &…

Kratos Defense & Security Solutions announced that it has recently received approximately $30M in contract awards for Command, Control, Computing, Communication, Combat, Intelligence, Surveillance and Reconnaissance Systems, focused primarily on missile defense related combat systems. Kratos is an industry leader in the rapid development, demonstration and fielding of affordable leading technology products and solutions in support of the United States and its allies' national security missions. Kratos C5ISR Modular Systems Business is an industry leader in manufacturing, producing and delivering C5ISR Systems for Missile, Radar, High Power Directed Energy, Ballistic Missile Defense, Unmanned Aerial Vehicle, Chemical, Biological, Radiation, Nuclear and High Explosive and other programs and applications. Work under these recent program awards will be performed at secure Kratos manufacturing and production facilities. The majority of the performance under these contract awards will be completed over the next 24 months. Due to customer, competitive and other considerations, no additional information will be provided related to these U.S. National Security related program awards.

ShowHide Related Items >><<
KTOS Kratos Defense
$15.33 /

-0.315 (-2.01%)

KTOS Kratos Defense
$15.33 /

-0.315 (-2.01%)

04/06/20 Canaccord
Kratos Defense acquisition provides long-term opportunity, says Canaccord
03/18/20 Benchmark
Benchmark starts Kratos Defense at Buy, sees 'commanding' lead in drones
03/18/20 Benchmark
Kratos Defense initiated with a Buy at Benchmark
03/11/20 SunTrust
Kratos Defense upgraded to Buy from Hold at SunTrust
KTOS Kratos Defense
$15.33 /

-0.315 (-2.01%)

  • 19
    Jun
KTOS Kratos Defense
$15.33 /

-0.315 (-2.01%)

Recommendations
PayPal price target raised to $200 from $176 at Wedbush » 08:05
07/02/20
07/02
08:05
07/02/20
08:05
PYPL

PayPal

$177.47 /

+3.29 (+1.89%)

Wedbush analyst Moshe…

Wedbush analyst Moshe Katri raised the firm's price target on PayPal to $200 from $176 and keeps an Outperform rating on the shares. The analyst believes 2020 and 2021's results will likely show accelerating revenue growth, reflecting more intensive/efficient monetization at Venmo. While prior monetization efforts targeted a consumer base of 52M accounts, a new feature will target SMBs, which he believes opens an entirely new merchants' universe for Paypal's eco-system, with incremental revenue opportunities from cross-selling, selling-fees, as well as advertising. PayPal is on the Wedbush Best Ideas List.

ShowHide Related Items >><<
PYPL PayPal
$177.47 /

+3.29 (+1.89%)

PYPL PayPal
$177.47 /

+3.29 (+1.89%)

06/30/20
Fly Intel: Top five analyst initiations
06/30/20 Canaccord
PayPal price target raised to $190 from $160 at Canaccord
06/30/20 Citi
PayPal remains a top idea at Citi
06/30/20 JMP Securities
PayPal initiated with an Outperform at JMP Securities
PYPL PayPal
$177.47 /

+3.29 (+1.89%)

PYPL PayPal
$177.47 /

+3.29 (+1.89%)

PYPL PayPal
$177.47 /

+3.29 (+1.89%)

PYPL PayPal
$177.47 /

+3.29 (+1.89%)

Hot Stocks
BNY Mellon announces collaboration with Early Warning Services » 08:05
07/02/20
07/02
08:05
07/02/20
08:05
BK

BNY Mellon

$37.57 /

-1.09 (-2.82%)

BNY Mellon announced a…

BNY Mellon announced a collaboration with risk and payments solution provider Early Warning Services. Through this agreement, BNY Mellon will deliver real-time account validation services to clients, and offer the flexibility to tailor a solution to meet clients' individual needs- whether through BNY Mellon directly, or through one of its Private Label Bank relationships.

ShowHide Related Items >><<
BK BNY Mellon
$37.57 /

-1.09 (-2.82%)

BK BNY Mellon
$37.57 /

-1.09 (-2.82%)

06/11/20 Deutsche Bank
BNY Mellon named short-term investment idea at Deutsche Bank
06/05/20 Wells Fargo
BNY Mellon price target raised to $47 from $40 at Wells Fargo
04/09/20 JPMorgan
BNY Mellon upgraded to Neutral with $41.50 price target at JPMorgan
04/09/20 JPMorgan
BNY Mellon upgraded to Neutral from Underweight at JPMorgan
BK BNY Mellon
$37.57 /

-1.09 (-2.82%)

BK BNY Mellon
$37.57 /

-1.09 (-2.82%)

BK BNY Mellon
$37.57 /

-1.09 (-2.82%)

BK BNY Mellon
$37.57 /

-1.09 (-2.82%)

Hot Stocks
Centogene receives EUA for COVID-19 molecular diagnostic test » 08:05
07/02/20
07/02
08:05
07/02/20
08:05
CNTG

Centogene

$25.20 /

+3.21 (+14.60%)

Centogene announced that…

Centogene announced that the U.S. Food and Drug Administration has issued Emergency Use Authorization (EUA) for the company's SARS-CoV-2 RT-PCR test.

ShowHide Related Items >><<
CNTG Centogene
$25.20 /

+3.21 (+14.60%)

CNTG Centogene
$25.20 /

+3.21 (+14.60%)

04/24/20 BTIG
Centogene price target raised to $23 from $18 at BTIG
04/24/20 Evercore ISI
Centogene downgraded to In Line from Outperform at Evercore ISI
12/03/19 Baird
Centogene initiated with an Outperform at Baird
12/02/19 BTIG
Centogene initiated with a Buy at BTIG
  • 07
    Nov
Hot Stocks
e.l.f. Beauty reaches cooperation agreement with Marathon, expands board to nine » 08:04
07/02/20
07/02
08:04
07/02/20
08:04
ELF

e.l.f. Beauty

$18.08 /

-1 (-5.24%)

e.l.f. Beauty announced…

e.l.f. Beauty announced that it has reached a cooperation agreement with Marathon Partners, an investment firm which beneficially owns approximately 5.2% of the company's outstanding common stock. Pursuant to the cooperation agreement, the board announced that it will be including a "say-on-pay" proposal, as well as a proposal regarding the frequency of future "say-on-pay" votes, both of which stockholders will be eligible to vote on at the upcoming 2020 annual meeting. Additionally, the company agreed to reduce the maximum automatic annual percentage increase of shares under the company's 2016 Equity Incentive Award Plan from 4% to 2%. The company also has appointed Lori Keith, portfolio manager of Parnassus Investments $5B Mid Cap Fund, as an independent director to the board and as a member of the nominating and corporate governance committee of the board, effective immediately. Keith has been appointed to serve as a Class III Director and will be standing for election at the company's 2022 annual meeting of stockholders. In connection with this appointment, the company has expanded the size of its board to nine directors, eight of whom are independent.

ShowHide Related Items >><<
ELF e.l.f. Beauty
$18.08 /

-1 (-5.24%)

ELF e.l.f. Beauty
$18.08 /

-1 (-5.24%)

06/25/20 Morgan Stanley
e.l.f. Beauty target raised to $22 at Morgan Stanley as scanner data outperforms
05/22/20 SunTrust
e.l.f. Beauty price target raised to $20 from $15 at SunTrust
04/08/20 Piper Sandler
Piper lays out winners and losers in survey of 5,200 teens
03/18/20 DA Davidson
e.l.f. Beauty price target lowered to $12 from $24.50 at DA Davidson
ELF e.l.f. Beauty
$18.08 /

-1 (-5.24%)

  • 03
    Dec
  • 29
    Aug
ELF e.l.f. Beauty
$18.08 /

-1 (-5.24%)

ELF e.l.f. Beauty
$18.08 /

-1 (-5.24%)

Hot Stocks
Gentherm, ThermoAnalytics partner for human thermal comfort predictions » 08:04
07/02/20
07/02
08:04
07/02/20
08:04
THRM

Gentherm

$38.16 /

-0.68 (-1.75%)

Gentherm and…

Gentherm and ThermoAnalytics announced the companies' joint efforts in developing advanced software to improve human thermal comfort predictions. There is an increased need and demand from consumers to provide a personalized experience when they enter a vehicle. Individual comfort varies from person to person, and the year-long partnership resulted in the development of new and improved software solutions that can accurately predict an individual's personalized comfort and wellness. The collaboration improved upon existing abilities to predict passenger comfort by modeling the human body in the cabin of the vehicle to increase the number of body parts measured. The partnership moved beyond thermal comfort predictions to include the effects of moisture on human comfort. This is the first-time software will have the ability to predict comfort and discomfort caused by sweat from the human body.

ShowHide Related Items >><<
THRM Gentherm
$38.16 /

-0.68 (-1.75%)

THRM Gentherm
$38.16 /

-0.68 (-1.75%)

06/19/20 JPMorgan
Gentherm price target raised to $39 from $34 at JPMorgan
05/12/20 Barrington
Gentherm outperforming relative to automotive industry, says Barrington
05/11/20 Roth Capital
Gentherm assumed with a Buy at Roth Capital
04/21/20 Craig-Hallum
Gentherm price target lowered to $38 from $50 at Craig-Hallum
THRM Gentherm
$38.16 /

-0.68 (-1.75%)

Recommendations
American Express price target raised to $85 from $78 at Compass Point » 08:03
07/02/20
07/02
08:03
07/02/20
08:03
AXP

American Express

$94.04 /

-0.28 (-0.30%)

Compass Point analyst…

Compass Point analyst William Ryan raised the firm's price target on American Express to $85 from $78 and keeps a Neutral rating on the shares. The analyst does not expect a Q2 loss to be high enough to generate concern about the sustainability of the company's dividend. To reflect spending and credit trends, Ryan reduced his 2020 estimate on American Express to $1.48 from $2.00. A strong reserve build will likely lead the company to report a loss on the bottom line for Q2, says the analyst.

ShowHide Related Items >><<
AXP American Express
$94.04 /

-0.28 (-0.30%)

AXP American Express
$94.04 /

-0.28 (-0.30%)

06/22/20
Fly Intel: Top five analyst downgrades
06/22/20 UBS
American Express downgraded to Sell from Neutral at UBS
06/18/20 DZ Bank
American Express downgraded to Hold from Buy at DZ Bank
06/08/20
Fly Intel: Top five analyst downgrades
AXP American Express
$94.04 /

-0.28 (-0.30%)

AXP American Express
$94.04 /

-0.28 (-0.30%)

AXP American Express
$94.04 /

-0.28 (-0.30%)

AXP American Express
$94.04 /

-0.28 (-0.30%)

Hot Stocks
Fuwei Films announces majority ownership transfer to Shanghai Meicheng » 08:03
07/02/20
07/02
08:03
07/02/20
08:03
FFHL

Fuwei Films

$5.43 /

+0.03 (+0.56%)

Fuwei Films received a…

Fuwei Films received a notification from Shanghai Meicheng Enterprise Management with respect to an ownership transfer from Shandong SNTON Group to Shanghai Meicheng of the company's 52.9% controlling outstanding ordinary shares. SNTON Group held the Shares indirectly through an intermediate holding company, Hongkong Ruishang. It is noted that SNTON Group transferred its equity in Hongkong Ruishang to Shanghai Meicheng on June 23 due to SNTON Group's asset reorganization. As a result of this transfer, Shanghai Meicheng now indirectly owns the Shares through Hongkong Ruishang. Hongkong Ruishang in turn holds the Shares through Apex Glory Holdings Limited, a British Virgin Islands corporation. Shanghai Meicheng is a diversified investment management company located in the Yuhaitang Science and Technology Park of Chongwen District in Shanghai, P.R. China.

Hot Stocks
Apellis completes enrollment in Phase 3 study of pegcetacoplan » 08:02
07/02/20
07/02
08:02
07/02/20
08:02
APLS

Apellis

$31.90 /

-0.73 (-2.24%)

Apellis Pharmaceuticals…

Apellis Pharmaceuticals announced the completion of enrollment in the global Phase 3 PRINCE study, which is evaluating pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria who are treatment-naive, meaning they had not received a complement inhibitor within three months before entering the trial. The PRINCE study is a Phase 3, randomized, multicenter, open-label, controlled trial. The study was designed to evaluate the efficacy of pegcetacoplan in 48 adult patients who are treatment-naive, showed evidence of hemolysis and had hemoglobin levels that were less than the lower limit of normal at the time of their screening. Primary outcome measures, to be evaluated after 26 weeks of treatment, include hemoglobin stabilization in the absence of transfusion and reduction in lactate dehydrogenase level. A total of 53 patients were enrolled in the study. Based on positive results from the pivotal PEGASUS study of pegcetacoplan in PNH, the company plans to submit marketing applications for pegcetacoplan for the treatment of PNH both in the United States and the European Union in the second half of 2020.

ShowHide Related Items >><<
APLS Apellis
$31.90 /

-0.73 (-2.24%)

APLS Apellis
$31.90 /

-0.73 (-2.24%)

06/16/20 BTIG
Apellis initiated with a Neutral at BTIG
06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
04/28/20 Cantor Fitzgerald
Apellis price target raised to $61 from $54 at Cantor Fitzgerald
04/01/20 Raymond James
Apellis initiated with a Strong Buy at Raymond James
APLS Apellis
$31.90 /

-0.73 (-2.24%)

  • 09
    Jan
APLS Apellis
$31.90 /

-0.73 (-2.24%)

APLS Apellis
$31.90 /

-0.73 (-2.24%)

Hot Stocks
Alaska Air secures approximately $1.2B in private loans » 08:02
07/02/20
07/02
08:02
07/02/20
08:02
ALK

Alaska Air

$35.71 /

-0.56 (-1.54%)

, BA

Boeing

$180.33 /

-3.05 (-1.66%)

, ERJ

Embraer

$6.05 /

+0.07 (+1.17%)

Alaska Airlines (ALK) has…

Alaska Airlines (ALK) has secured nearly $1.2B in private loans to further secure its financial stability and future during the COVID-19 recovery period, while balancing the appropriate amount of liquidity. The debt financing will be funded on or around July 2. As part of an Enhanced Equipment Trust Certificate offering, Alaska will use 61 of its owned aircraft as collateral to back the debt: 26 Boeing (BA) 737-800s, 16 Boeing 737-900ERs and 19 Embraer (ERJ) 175s. The aircraft will remain encumbered until the debt is repaid: Series A ($966M) will be repaid by Aug. 15, 2027, and Series B ($208M) will be repaid by Aug. 15, 2025.

ShowHide Related Items >><<
ERJ Embraer
$6.05 /

+0.07 (+1.17%)

BA Boeing
$180.33 /

-3.05 (-1.66%)

ALK Alaska Air
$35.71 /

-0.56 (-1.54%)

ALK Alaska Air
$35.71 /

-0.56 (-1.54%)

06/29/20 Goldman Sachs
Alaska Air price target raised to $63 from $51 at Goldman Sachs
06/22/20 Raymond James
Alaska Air price target raised to $44 from $40 at Raymond James
06/16/20 Stifel
United loyalty deal raises odds of survival without restructuring, says Stifel
06/10/20 JPMorgan
Alaska Air price target raised to $54 from $43 at JPMorgan
BA Boeing
$180.33 /

-3.05 (-1.66%)

06/26/20
Fly Intel: Top five analyst downgrades
06/26/20 RBC Capital
Spirit AeroSystems initiated with an Outperform at RBC Capital
06/26/20 Bernstein
Boeing downgraded to Market Perform from Outperform at Bernstein
06/25/20
Fly Intel: Top five analyst downgrades
ERJ Embraer
$6.05 /

+0.07 (+1.17%)

05/04/20 BofA
Embraer downgraded to Neutral from Buy at BofA
04/28/20 Credit Suisse
Embraer downgraded to Underperform from Neutral at Credit Suisse
04/27/20 Bradesco BBI
Embraer downgraded to Underperform from Outperform at Bradesco
04/09/20
Fly Intel: Top five analyst upgrades
ERJ Embraer
$6.05 /

+0.07 (+1.17%)

BA Boeing
$180.33 /

-3.05 (-1.66%)

ALK Alaska Air
$35.71 /

-0.56 (-1.54%)

ERJ Embraer
$6.05 /

+0.07 (+1.17%)

BA Boeing
$180.33 /

-3.05 (-1.66%)

ALK Alaska Air
$35.71 /

-0.56 (-1.54%)

ERJ Embraer
$6.05 /

+0.07 (+1.17%)

BA Boeing
$180.33 /

-3.05 (-1.66%)

ALK Alaska Air
$35.71 /

-0.56 (-1.54%)

BA Boeing
$180.33 /

-3.05 (-1.66%)

ALK Alaska Air
$35.71 /

-0.56 (-1.54%)

Recommendations
Wix.com price target raised to $300 from $275 at Wedbush » 08:02
07/02/20
07/02
08:02
07/02/20
08:02
WIX

Wix.com

$265.63 /

+9.24 (+3.60%)

, SHOP

Shopify

$1,016.39 /

+65.94 (+6.94%)

Wedbush analyst Ygal…

Wedbush analyst Ygal Arounian raised the firm's price target on Wix.com (WIX) to $300 from $275 and keeps an Outperform rating on the shares. The analyst notes that Wix has announced the launch of a bundled e-commerce product, which he believes opens up the company's addressable market, as it becomes a more viable tool for SMBs that need stronger e-commerce capabilities. Further, Arounian thinks Wix e-commerce becomes a comparable solution to Shopify's (SHOP) non-Plus tiers. It's a significant step in the right direction, he contends, as it should position Wix as an alternative to Shopify for low to middle market SMBs that don't need the complexities of an enterprise solution.

ShowHide Related Items >><<
WIX Wix.com
$265.63 /

+9.24 (+3.60%)

SHOP Shopify
$1,016.39 /

+65.94 (+6.94%)

WIX Wix.com
$265.63 /

+9.24 (+3.60%)

06/29/20 SunTrust
Wix.com price target raised to $290 from $215 at SunTrust
06/24/20 KeyBanc
Wix.com price target raised to $275 from $250 at KeyBanc
06/09/20 KeyBanc
Wix.com upgraded to Overweight from Sector Weight at KeyBanc
05/27/20 Guggenheim
Wix.com price target raised to $230 from $200 at Guggenheim
SHOP Shopify
$1,016.39 /

+65.94 (+6.94%)

07/02/20 Baird
Shopify price target raised to $1,100 from $820 at Baird
07/01/20 Argus
Shopify initiated with a Buy at Argus
07/01/20 Argus
Shopify initiated with a Buy at Argus
06/29/20 Goldman Sachs
Shopify price target raised to $1,127 from $786 at Goldman Sachs
WIX Wix.com
$265.63 /

+9.24 (+3.60%)

SHOP Shopify
$1,016.39 /

+65.94 (+6.94%)

  • 08
    May
  • 17
    Sep
SHOP Shopify
$1,016.39 /

+65.94 (+6.94%)

WIX Wix.com
$265.63 /

+9.24 (+3.60%)

SHOP Shopify
$1,016.39 /

+65.94 (+6.94%)

WIX Wix.com
$265.63 /

+9.24 (+3.60%)

SHOP Shopify
$1,016.39 /

+65.94 (+6.94%)

Recommendations
Wedbush boosts Tesla target to $1,250 with new bull case of $2,000 » 08:00
07/02/20
07/02
08:00
07/02/20
08:00
TSLA

Tesla

$1,118.00 /

+39 (+3.61%)

Wedbush analyst Daniel…

Wedbush analyst Daniel Ives raised the firm's price target on Tesla to $1,250 from $1,000 and keeps a Neutral rating on the shares. The analyst's "bull case" is now $2,000. Tesla closed Wednesday up $39.82 to $1,119.63. With demand for Model 3's "ramping stronger than expectations" in China heading into the summer, the lockdown easing in the U.S. and Europe, and some potentially "game changing" battery developments on the horizon, Tesla's stock "likely has room to run further," Ives tells investors in a research note. The analyst believes the "main fundamental catalyst" for the stock continues to be the "massive" China market, which he notes is showing "clear signs of a spike in demand." The Street is looking for 70,000 deliveries in Q2, and with a "very strong end to the quarter likely," Tesla could now be in the 85,000 to 90,000. Such a range could put the company's bottom-line" in the area code of breakeven," which is a "jaw dropping feat in a dark macro and COVID backdrop," contends Ives. The analyst's new price target reflects "increased confidence in the Tesla story and delivery trajectory." Further, he believes the China growth story is worth at least $300 per share and $400 in a bull case to Tesla.

ShowHide Related Items >><<
TSLA Tesla
$1,118.00 /

+39 (+3.61%)

TSLA Tesla
$1,118.00 /

+39 (+3.61%)

07/01/20 Wedbush
'Impressive' trajectory in June bodes well for Tesla deliveries, says Wedbush
06/30/20 Oppenheimer
Oppenheimer anticipates in-line or ahead of consensus Q2 deliveries for Tesla
06/30/20 JMP Securities
Tesla price target raised to $1,050 from $1,001 at JMP Securities
06/29/20 Bernstein
Tesla Semi rollout could be more modest, take longer, says Bernstein
TSLA Tesla
$1,118.00 /

+39 (+3.61%)

  • 14
    Feb
TSLA Tesla
$1,118.00 /

+39 (+3.61%)

TSLA Tesla
$1,118.00 /

+39 (+3.61%)

TSLA Tesla
$1,118.00 /

+39 (+3.61%)

TSLA Tesla
$1,118.00 /

+39 (+3.61%)

Hot Stocks
Tesla reports Q2 production of 82,000 vehicles, delivery of 90,650 vehicles » 08:00
07/02/20
07/02
08:00
07/02/20
08:00
TSLA

Tesla

$1,118.00 /

+39 (+3.61%)

The company said,…

The company said, "In the second quarter, we produced over 82,000 vehicles and delivered approximately 90,650 vehicles. While our main factory in Fremont was shut down for much of the quarter, we have successfully ramped production back to prior levels.. Our net income and cash flow results will be announced along with the rest of our financial performance when we announce Q2 earnings. Our delivery count should be viewed as slightly conservative, as we only count a car as delivered if it is transferred to the customer and all paperwork is correct. Final numbers could vary by up to 0.5% or more. Tesla vehicle deliveries represent only one measure of the company's financial performance and should not be relied on as an indicator of quarterly financial results, which depend on a variety of factors, including the cost of sales, foreign exchange movements and mix of directly leased vehicles."

ShowHide Related Items >><<
TSLA Tesla
$1,118.00 /

+39 (+3.61%)

TSLA Tesla
$1,118.00 /

+39 (+3.61%)

07/01/20 Wedbush
'Impressive' trajectory in June bodes well for Tesla deliveries, says Wedbush
06/30/20 Oppenheimer
Oppenheimer anticipates in-line or ahead of consensus Q2 deliveries for Tesla
06/30/20 JMP Securities
Tesla price target raised to $1,050 from $1,001 at JMP Securities
06/29/20 Bernstein
Tesla Semi rollout could be more modest, take longer, says Bernstein
TSLA Tesla
$1,118.00 /

+39 (+3.61%)

  • 14
    Feb
TSLA Tesla
$1,118.00 /

+39 (+3.61%)

TSLA Tesla
$1,118.00 /

+39 (+3.61%)

TSLA Tesla
$1,118.00 /

+39 (+3.61%)

TSLA Tesla
$1,118.00 /

+39 (+3.61%)

Hot Stocks
Aquestive CEO sees 'no reason' to believe Libervant PDUFA will be delayed » 08:00
07/02/20
07/02
08:00
07/02/20
08:00
AQST

Aquestive Therapeutics

$4.75 /

-0.11 (-2.26%)

Aquestive Therapeutics…

Aquestive Therapeutics (AQST) is a pharmaceutical company committed to developing and commercializing products to address unmet medical needs. In an exclusive interview with The Fly, Aquestive President and CEO Keith Kendall discussed the company's Libervant: "As we have indicated previously, the NDA for Libervant was filed in November 2019 and the FDA has assigned a PDUFA goal date of late September 2020. As an organization, we worked closely with the FDA during the development process to do our best to provide the information that the FDA needs to approve our product. However, there can be no assurances with regard to the FDA decision regarding our application. The review to-date has progressed as we would have expected, with a normal exchange of information requests and answers to the requests. We expect that this will continue as we move closer to the September date. At this time, we have no indication or reason to believe that there will be any delay." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

ShowHide Related Items >><<
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

  • 13
    Dec
AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

AQST Aquestive Therapeutics
$4.75 /

-0.11 (-2.26%)

Options
United Continental put buyer realizes 77% same-day gains » 08:00
07/02/20
07/02
08:00
07/02/20
08:00
UAL

United Airlines

$34.44 /

-0.18 (-0.52%)

Notable profits for the…

Notable profits for the buyer who lifted the $1.29 offer for 1,038 United Continental (UAL) 7/10 weekly 35 puts yesterday at 10:25ET when underlying shares were trading at $36.74. Shares closed at $34.45, and the puts at $2.29 for a mark-to-market profit of 77%, or $103K, on the $134K outlay.

ShowHide Related Items >><<
UAL United Airlines
$34.44 /

-0.18 (-0.52%)

UAL United Airlines
$34.44 /

-0.18 (-0.52%)

06/29/20 Goldman Sachs
United Airlines price target raised to $61 from $40 at Goldman Sachs
06/17/20
Fly Intel: Top five analyst initiations
06/17/20 Seaport Global
United Airlines initiated with a Buy at Seaport Global
06/16/20 Stifel
United loyalty deal raises odds of survival without restructuring, says Stifel
UAL United Airlines
$34.44 /

-0.18 (-0.52%)

  • 22
    Apr
UAL United Airlines
$34.44 /

-0.18 (-0.52%)

UAL United Airlines
$34.44 /

-0.18 (-0.52%)

UAL United Airlines
$34.44 /

-0.18 (-0.52%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.